December 2016
-
RDD 2021 has moved to a virtual format. Limited live programming will place May 4-7; some aspects of the meeting, including on-demand poster presentations, will continue through June 30. Submit poster abstracts on any topic… Read more . . .
-
Posted on OINDPnews on December 2, 2020 Company: Sandoz Job Description 600 million people worldwide suffer from asthma and COPD. Many of the innovative drugs are expensive. Sandoz is committed to providing affordable generic medicines… Read more . . .
-
Regeneron Pharmaceuticals is collaborating with researchers at the University of Pennsylvania (Penn) to study the feasibility of intranasal delivery of Regeneron’s casirivimab and imdevimab antibody cocktail for the prevention of COVID-19, the university said. The… Read more . . .
-
Kindeva Drug Delivery has announced a new agreement with Israeli medical cannabis company Breath of Life International (BOL Pharma) for development of formulations of several cannabinoids for delivery via Kindeva MDIs. The formulations will initially… Read more . . .
-
Codagenix announced that it has completed dosing in a Phase 1 clinical trial of its intranasal CodaVax-RSV vaccine for the prevention of respiratory syncytial virus (RSV). According to Codagenix, its SAVE (Synthetic Attenuated Virus Engineering)… Read more . . .
-
According to ARS Pharmaceuticals, the EMA has accepted the company’s marketing authorization application for its Neffy (ARS-1) epinephrine nasal spray for the emergency treatment of anaphylaxis. ARS recently announced that Recordati had acquired marketing rights… Read more . . .
-
US-based startup Kinaset Therapeutics has signed a licensing and develop an inhaled pan-JAK inhibitor that was in Vectura’s pipeline prior to that company’s transformation into an inhalation CDMO. In July 2019, Vectura announced that it… Read more . . .
-
Dr. Reddy’s Laboratories said that it has acquired several mometasone and mometasone/azelastine nasal sprays for the treatment of seasonal and perennial allergic rhinitis from Glenmark for Russia, Kazakhstan, Uzbekistan, and Ukraine. The brands included in… Read more . . .
-
Nanoform Finland has announced the launch of new nanonization technology that is capable of creating biological nanoparticles down to 50 nm. The company said that it has filed for US patents covering the technology and… Read more . . .
-
MSP, a division of TSI, has announced the launch of an enhanced Next Generation Impactor (NGI) called the NGI+, which is designed for improved resistance to corrosion and longer life expectancy. According to MSP, which… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland